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A B S T R A C T   
Oral candidiasis is frequently associated with Candida biofilms. Biofilms are microbial communities related to 
persistent, recalcitrant and difficult to-treat infections. Conventional treatments are not sufficient to overcome 
biofilm-associated candidiasis; thus, the search of new antifungal compounds is necessary. In the current study, 
we have evaluated the effect of three phytocompounds, carvacrol, cinnamaldehyde and thymol, against Candida 
planktonic and sessile cells. Reduction in biofilm biomass and metabolic activity was assessed during adhesion 
and mature biofilm phases. Candida albicans was the most biofilm-producing Candida species. All phyto-
compounds tested were fungicidal against Candida planktonic cells. Cinnamaldehyde was the most active in 
inhibiting biofilm adhesion, but carvacrol and thymol significantly reduced both mature biofilm biomass and 
metabolic activity. These results highlight the role of cinnamaldehyde, carvacrol and thymol as promising al-
ternatives for the treatment of candidiasis due to their antibiofilm capacities, and stress the necessity to continue 
studies on their safety, toxicity and pharmacodynamics and pharmacokinetics.   
1. Introduction 
Oral candidiasis is one of the most prevalent opportunistic infections 
that causes oral discomfort, pain and dysgeusia and it is often associated 
with a poor immune status that can lead to complications, such as 
esophageal or systemic candidiasis [1–3]. Risk for systemic infection 
increases in immunocompromised patients colonized by Candida. 
Although most oral infections are easily treatable, they often follow a 
protracted course in those patients carrying dentures, HIV-infected or 
under chemotherapy [2]. Treatment of oral candidiasis is based on the 
correction of underlying diseases, the maintenance of good oral hygiene 
and the use of antifungal drugs. Candida albicans is the most frequent 
etiology, followed by Candida glabrata [1,4]. C. albicans outstands in the 
oral cavity due in part to its biofilm forming ability that challenges the 
efficacy of treatment. Extracellular polymeric substances, such as 
carbohydrate and extracellular DNA, often hamper antifungal penetra-
tion through biofilms extracellular matrix (ECM). This clinical concern is 
magnified by the emergence of azole resistant isolates and by the se-
lection of species of Candida with reduced antifungal susceptibility [3]. 
In recent years, essential oils and their components have gathered sig-
nificant attention as potential antimicrobial agents due to its relative 
safety, low long-term genotoxicity and scarcity of side effects [5]. Main 
strategies focus on studying the effectiveness of key phytocompounds 
against Candida biofilms as monotherapy or in combination with current 
antifungal drugs, thus limiting development of resistance or decreasing 
antifungal selective pressure. Some phytocompounds have been 
included in rinses or mouthwashes for preventing oral infections [6]. 
However, most studies evaluate the activity of essential oils as a whole, 
rather than studying key components, which could be more advanta-
geous in safety and reproducibility [7]. Therefore, the aim of the present 
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study was to assess the in vitro activity of carvacrol, cinnamaldehyde and 
thymol, compared to anidulafungin, fluconazole and isavuconazole, 
against planktonic and sessile Candida cells. 
2. Materials and methods 
2.1. Microorganisms 
Thirty-five oral isolates from patients suffering oral candidiasis attending 
the Dental Clinic Service at the Universidad del País Vasco/Euskal Herriko 
Unibertsitatea (UPV/EHU), Bilbao (Spain) were analyzed. Isolates were 
identified by conventional techniques, such as colony morphology on 
Candida Chromogenic agar (Laboratorios Conda, Spain) and ChromID 
Candida (BioMérieux, France), carbon source assimilation kit API ID 32C 
system (BioMérieux), and molecular methods (Multiplex PCR and PCR- 
RFLP to C. glabrata complex and C. parapsilosis complex, respectively) [4]. 
These isolates included 10 C. albicans, 10 C. glabrata, three isolates each of 
Candida dubliniensis and Candida krusei, two isolates each of Candida guil-
liermondii, Candida orthopsilosis, Candida parapsilosis and Candida tropicalis, 
and one Candida metapsilosis. Moreover, seven reference strains from the 
American Type Culture Collection (ATCC) and the National Collection of 
Pathogenic Fungi (NCPF), and the hypha-defective mutant C. albicans Ca2 
(kindly donated by Professor Antonio Cassone, Istituto Superiore di Sanità, 
Rome, Italy) were studied. Isolates and reference strains were cultured on 
Sabouraud dextrose agar (Difco, Becton Dickinson, USA) at 37 ◦C for 24 h 
before testing. 
2.2. Biofilm production 
Biofilm production by oral isolates and reference strains was assessed. 
Prior to each experiment, they were cultured overnight at 30 ◦C in an 
orbital shaker on yeast peptone dextrose (YPD) medium containing 1% 
weight/volume (w/v) yeast extract, 2% w/v peptone and 2% w/v dextrose. 
Cells were washed thrice in sterile phosphate buffered saline solution 
(PBS), and adjusted to a cellular density of 1.0 × 106 cells/ml in RPMI-1640 
supplemented with L-glutamine and buffered at pH 7 with 0.165 M 3-(N- 
morpholino)propanesulfonic acid, MOPS (Sigma-Aldrich). Candida bio-
films were developed in sterilized, flat-bottomed honeycomb 100-well 
polystyrene microtiter plates (Labsystems, Finland) by adding 100 µl of 
the adjusted standard cell suspension into each well. Two identical mi-
crotiter plates were prepared, one to determine metabolic activity and the 
other to quantify biomass. Microtiter plates were incubated at 37 ◦C in a 
computer-controlled incubator (BioScreen C MBR, Growth Curves Ltd, 
Finland). After 24 and 48 h non-adherent and loosely adherent cells were 
removed by washing three times with sterile PBS. 
2.2.1. Metabolic activity determination assay 
Metabolic activity of the biofilm was measured following the colori-
metric method described by Ramage et al. [8]. The 2,3-bis(2-methoxy-4-ni-
tro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT, Sigma-Aldrich) 
reagent was prepared as a saturated solution at 0.5 g/l in Ringer’s lactate 
and the solution was sterilized by filtration, aliquoted and stored at − 70 ◦C 
until required. Before each assay, an aliquot of stock XTT was thawed and 
menadione was added to a final concentration of 1 μM. Then, 100 µl of 
XTT-menadione was added to each prewashed well and incubated in dark 
for 2 h at 37 ◦C. The colorimetric changes showing metabolic activity of the 
biofilm were measured on the microtiter plate reader BioScreen C MBR at 
490 nm wavelengths. 
2.2.2. Biomass quantification assay 
Biomass quantification was performed following the method 
described by Peeters et al. [9] using crystal violet. After removing 
non-adherent cells, microplates were air-dried for 30 min and then, 100 
µl of 0.4% crystal violet solution was added to each well and incubated 
for a further 20 min at room temperature. Microplates were washed 
twice using 250 µl of sterile distilled water and 150 µl of 33% acetic acid 
were afterwards added to each well. Absorbance of the biomass was 
measured at 600 nm wavelengths. 
2.3. Phytocompounds and antifungal agents 
Carvacrol, cinnamaldehyde and thymol at 98%, 95% and 99% pu-
rity, respectively, were purchased from Sigma-Aldrich. Anidulafungin 
(Pfizer, Spain), fluconazole (Sigma-Aldrich) and isavuconazole (Basilea 
Pharmaceutica, Switzerland) were also used. 
Stock solutions were prepared in dimethylsulfoxide (DMSO, Sigma- 
Aldrich). Antifungal drugs were stored at − 70 ºC and phytocompounds 
were prepared on the same day of the susceptibility test. The tested 
compounds contained 0.5% DMSO, therefore all drug-free controls also 
included this concentration of DMSO. 
2.4. In vitro antifungal activity against planktonic cells 
In vitro antifungal susceptibility was assessed according to the method-
ology proposed by the European Committee for Antimicrobial Susceptibility 
Testing [10,11]. Final concentrations of anidulafungin ranging from 0.016 
to 8 mg/l, of fluconazole from 0.12 to 64 mg/l and of isavuconazole from 
0.016 to 8 mg/l were used. Susceptibility to carvacrol, cinnamaldehyde and 
thymol was assayed at concentrations ranging from 2 to 1024 mg/l. C. krusei 
ATCC 6258 and C. parapsilosis ATCC 22019 were used as quality controls. 
Absorbance of each microplate was measured at 450 nm wavelengths by the 
iMark reader (BioRad, USA) after 24 and 48 h of incubation at 37 ◦C. 
Absorbance values equal to or less than 0.2 after 48 h were considered a 
failed test. Antifungal activities were studied in triplicate and in at least three 
separate experiments. Anidulafungin, fluconazole and isavuconazole mini-
mum inhibitory concentrations (MIC) were calculated at 24 h as the lowest 
drug concentration inhibiting ≥50% of growth in comparison to controls 
without antifungal drugs [10,11]. Carvacrol, cinnamaldehyde and thymol 
inhibitory concentrations (IC) were calculated at 24 h as the lowest drug 
concentration inhibiting ≥50% of growth in comparison to controls without 
phytocompounds [12]. Clinical isolates were classified as susceptible, 
susceptible-dose dependent and resistant using the species-specific MIC 
breakpoints defined by EUCAST for anidulafungin and fluconazole [13]. 
However, EUCAST breakpoints for isavuconazole have not been established. 
Minimum fungicidal concentration (MFC) was calculated by seeding 
100 µl of each well without growth onto Sabouraud dextrose agar plates 
[14]. Fungicidal activity was defined as the lowest concentration of 
antifungal agent resulting in the death of 99.9% of the inoculum. 
2.5. Effect of phytocompounds against adhesion and mature Candida 
biofilms 
Ten clinical isolates were selected according to their biofilm pro-
duction in the previous assay: eight C. albicans and one isolate each of 
C. dubliniensis and C. tropicalis. C. albicans SC5314 and the hypha- 
deficient C. albicans Ca2 were included as controls. Activities of carva-
crol, cinnamaldehyde and thymol to prevent Candida biofilm formation 
were assessed according to the method described by Van Dijck et al. 
[12]. Briefly, 100 µl of the adjusted standard cell suspension of each 
isolate were inoculated into the 100-well polystyrene microtiter plates 
plus 100 µl of the phytocompound at final concentrations ranging from 8 
to 1024 mg/l. Pre-sessile ICs (PSICs) were those concentrations causing 
50% metabolic inhibition and 50% biomass reduction with respect to 
controls without compound. 
For the susceptibility assay against the sessile cells of the mature 
biofilm, concentrations of phytocompound ranging from 16 to 2048 mg/ 
l were used. Briefly, biofilms were developed into 100-well polystyrene 
microtiter plates by adding 100 µl of the adjusted Candida inoculum into 
each well. After an incubation of 24 h at 37 ◦C, non-adherent and loosely 
adherent cells were removed from the mature biofilm by washing twice 
with sterile PBS. Then, 100 µl of the final concentrations of phyto-
compounds in RPMI medium were added into microtiter plates for a 
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further incubation of 24 h at 37 ◦C. Compound-free wells and biofilm- 
free wells were also included as positive and negative controls, respec-
tively. Sessile ICs (SICs) were those concentrations causing 50% meta-
bolic inhibition and 50% biomass reduction with respect to controls. 
2.6. Morphology and architecture of the biofilm 
Morphology and architecture of the mature 24 h biofilms of 
C. albicans SC5314 strain developed on nitrocellulose filters of 13 mm 
(Merck Millipore, Germany) or 8-well tissue culture chambers (Sarstedt, 
Germany) were studied by scanning electron microscopy (SEM) and 
confocal microscopy (CLSM), respectively. Mature biofilms were also 
treated with 2048 mg/l of carvacrol, cinnamaldehyde and thymol to 
observe the effect on Candida biofilms by SEM and CLSM. 
Samples analyzed by SEM were fixed in 2% glutaraldehyde phos-
phate buffer solution. After three washes with 6% sucrose in Sorenson’s 
buffer, biofilms were dehydrated using graded ethanol solutions (50% 
and 70% in distilled water, and 100%) for 5 min each, and washed three 
times in hexamethyldisilazane (Electron Microscopy Sciences, USA) 
before air drying. Afterwards, samples were mounted on SEM stubs and 
gold coated using an Emitech k550x ion sputter. Finally, images were 
acquired using a Hitachi S-4800 scanning electron microscope. 
Biofilms analyzed by CLSM were stained with the LIVE/DEAD Yeast 
Viability Kit (Thermo Fisher Scientific S.L., USA) using FUN-1 and cal-
cofluor white M2R following the instructions of manufacturers. Briefly, 
biofilms formed on the 8-well tissue culture chambers slides were 
washed with buffer HEPES (10 mM Na-HEPES; pH: 7.2, with 2% 
glucose). Subsequently 500 µl of FUN-1 and M2R white calcofluor so-
lution (1:5) in HEPES buffer were dispensed into each well. Samples 
were incubated in dark for 30 min and afterwards, they were observed 
with standard filter set of FICT and DAPI by an Olympus Fluoview 
FV500 confocal microscope. Live cells show green color and dead cells 
yellow or orange. 
2.7. Statistical analysis 
Statistics were analyzed using Graphpad Prism 5.0 version (Graph-
Pad Software, USA). Comparisons between quantitative results were 
analyzed by t Student’s test when data showed a normal distribution and 
non-parametric Kruskal Wallis test with Dunn’s multiple comparison 
test and Mann Whitney non-parametrical test when data did not show a 
normal distribution. In all the cases, p < 0.05 was considered statisti-
cally significant. 
3. Results 
3.1. Biofilm production of oral Candida isolates 
Biofilm production of 35 isolates and reference strains was divided 
into terciles for CV and XXT assays. It allowed the classification of iso-
lates as high biomass (HBB) or high metabolically active (HMA) biofilm 
producers when the mean absorbance (OD) was greater than 0.500; 
moderate biomass (MBB) or with moderate metabolic activity (MMA) 
biofilm producers when absorbance ranged between 0.300 and 0.499, 
and low biomass (LBB) or low metabolically active (LMA) biofilm pro-
ducers when the mean values of the absorbance were less than 0.300 for 
each method (Fig. 1, Table S1). C. albicans isolates developed the most 
metabolically active biofilm and showed the highest biomass produc-
tion, including the isolate resistant to fluconazole and with reduced 
susceptibility to isavuconazole C. albicans UPV 15–157, classified as HBB 
and HMA biofilm producer. Highest biofilm producers among C. glabrata 
isolates exhibited moderate biofilm production (MBB and MMA). 
C. dubliniensis UPV 11–366, a fluconazole resistant isolate and with 
reduced susceptibility to isavuconazole was HMA and HBB, while two 
C. tropicalis isolates (UPV 06–115 and UPV 05–016) and C. parapsilosis 
UPV 12–296 were HBB but their biofilms showed moderate or low 
metabolic activities. All isolates of C. guilliermondii, C. krusei and the rest 
of species inside the C. parapsilosis complex produced biofilms with low 
or moderate metabolic activity and biomass. 
C. albicans produced more biofilm than C. krusei, C. glabrata and 
C. parapsilosis complex (p < 0.0005). Nevertheless, no significant dif-
ferences were found in biofilm production among C. albicans, 
C. tropicalis, C. dubliniensis and C. guilliermondii. 
3.2. In vitro antifungal susceptibility testing against Candida planktonic 
cells 
Table 1 shows the MIC and IC at 24 h of all oral isolates and reference 
strains. Carvacrol, cinnamaldehyde and thymol showed antifungal ac-
tivity against planktonic cells of all isolates (geometric mean -GM- of IC 
were 105 mg/l; 61.5 mg/l and 93.2 mg/l, respectively), including those 
resistant to fluconazole isolates (C. albicans UPV 15–157 and 
C. dubliniensis UPV 11–366), and susceptible-dose dependent and flu-
conazole resistant isolates of C. glabrata and C. krusei. Cinnamaldehyde 
was active against the 90% of isolates studied at 64 mg/l (IC90), fol-
lowed by thymol and carvacrol (IC90 128 mg/l for both compounds); 
therefore, cinnamaldehyde was the most active against all Candida 
Fig. 1. Biomass (A) and metabolic activity (B) of Candida biofilms. Percentages and number de isolates of each Candida species. Isolates were classified as high 
(HBB), moderate (MBB) and low (LBB) biomass biofilm producers; and with high (HMA), moderate (MMA) and low (LMA) metabolic activity. 





In vitro activity of carvacrol, cinnamaldehyde, thymol and current antifungal drugs against 35 isolates of Candida.  












C. albicans (10) IC GM 128 59.7 104.0 MIC GM 0.02 0.03 0.35 
Mode 128 64 128 Mode 0.016 0.016 0.25 
Range IC 128 32–64 32–256 Range MIC 0.016–0.03 0.016–8 0.12 – >64 
C. glabrata (10) IC GM 119.4 68.6 111.4 MIC GM 0.04 0.09 12.1 
Mode 128 64 128 Mode 0.06 0.125 16 
Range IC 16–512 64–128 32–128 Range MIC 0.03–0.06 0.03–0.5 4 – >64 
C. krusei (3) IC GM 80.6 50.8 64 MIC GM 0.04 0.1 50.8 
Mode 128 64 – Mode 0.03 0.125 64 
Range IC 32–128 32–128 32–128 Range MIC 0.03–0.06 0.06–0.12 32 – >64 
C. dubliniensis (3) IC GM 128 64 64 MIC GM 0.02 0.13 1 
Mode 128 64 64 Mode 0.03 0.016 0.125 
Range IC 128 64 64 Range MIC 0.016–0.03 0.016–8 0.12 – >64 
C. parapsilosis (2) IC GM 64 90.5 90.5 MIC GM 2 0.02 0.5 
Range IC 64 64–128 64–256 Range MIC 0.03–2 0.016–0.5 0.5–2 
C. guilliermondii (2) IC GM 64 64 90.5 MIC GM 0.25 0.24 4 
Range IC 64 64 64–128 Range MIC 0.25 0.12–0.5 2–8 
C. orthopsilosis (2) IC GM 64 32 64 MIC GM 0.5 0.016 0.4 
Range IC 64 32 64 Range MIC 0.5 0.016 0.25–0.5 
C. tropicalis (2) IC GM 128 64 128 MIC GM 0.02 0.016 5.7 
Range IC 128 64 128 Range MIC 0.016–0.03 0.016 0.5 – >64 
C. metapsilosis (1) IC 64 256 64 MIC 0.25 0.016 2 
Total IC GM 105 61.5 93.2 MIC GM 0.05 0.05 2.4 
Mode 128 64 128 Mode 0.016 0.016 0.125 
Range IC 16–512 32–128 32–256 Range MIC 0.016–2 0.016–8 0.12 – >64 
IC: inhibitory concentration, GM: geometric mean, MIC: minimum inhibitory concentration. 
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species except C. metapsilosis (IC 256 mg/l). The activity of all phyto-
compounds was fungicidal against Candida planktonic cells (Table 2). 
Cinnamaldehyde was the most effective agent, followed by thymol and 
carvacrol (GM MFC: 99.0 mg/l, 241.2 mg/l and 251.0 mg/l, 
respectively). 
3.3. In vitro antifungal susceptibility testing against Candida sessile cells 
Ten clinical isolates, including eight C. albicans (one fluconazole 
resistant), one fluconazole resistant C. dubliniensis and one C. tropicalis, 
were selected for their high biofilm production to study the effect of 
phytocompounds and antifungal agents against adhesion and preformed 
biofilms (Table 3). Anidulafungin was active reducing both the biomass 
and the metabolic activity in the adhesion phase of Candida biofilm 
formation of all isolates (GM PSMIC 0.134 and 0.125 mg/l, respec-
tively). Carvacrol, cinnamaldehyde and thymol were active inhibiting 
the metabolic activity of the adhesion phase (GM PSIC 104 mg/l, 
97 mg/l and 157.6 mg/l); as well as reducing the biomass, in which the 
cinnamaldehyde was the most effective (GM PSIC 111.4 mg/l), although 
thymol and carvacrol also showed good activity (GM PSIC 147 mg/l and 
157.6 mg/l, respectively). 
Fig. 2 shows mature biofilm growth inhibition of ten Candida isolates 
analyzed by biomass and metabolic activity determination assays. Ani-
dulafungin and cinnamaldehyde showed activity inhibiting the meta-
bolic activity but were less effective reducing biomass (GM SMIC 
0.9 mg/l with XTT and 29.6 mg/l ml with CV; GM SIC 118.5 mg/l with 
XTT and 1896.2 mg/l with CV assays, respectively). Conversely, 
carvacrol and thymol reduced the biomass of most of the mature bio-
films, and also showed activity inhibiting metabolic activity (GM SIC 
188.1 mg/l with XTT and 812.7 mg/l with CV; 128 mg/l with XTT and 
1106 mg/l with CV assays, respectively); while isavuconazole was less 
active reducing biomass and metabolic activity of mature biofilms. 
All phytocompounds were effective against the azole-resistant 
Candida isolates inhibiting significantly the metabolic activity of 
mature biofilm, with a reduction of 80% or more with the highest 
concentration assayed (2048 mg/l, Fig. 2). Moreover, a significant 
reduction was observed with 64 mg/l of the three phytocompounds 
against C. albicans UPV 15–157 isolate, and from the lowest concen-
tration (16 mg/l) against C. dubliniensis UPV 11–366 isolate and against 
the susceptible isolates. 
3.4. Morphology and architecture of the biofilm after treatment with 
phytocompounds 
Fig. 3 shows the cell morphology and the changes in the ultrastruc-
ture of the mature C. albicans SC5314 biofilm treated with the respective 
SIC of carvacrol, cinnamaldehyde and thymol (2048 mg/l) observed by 
SEM. Untreated Candida biofilm presented filamentation, abundant 
hyphae with well-defined shapes and oval shaped yeast cells with 
smooth surfaces and polar bud scars. In biofilms treated with all phy-
tocompounds, damage was evident presenting deformed hyphae, 
irregular surfaces in some sites with deposit of lytic material, reduction 
of number of cells and absence of hypha production. Untreated and 
treated biofilm showed absence of ECM due to dehydration during SEM 
procedures. 
The mature biofilm of C. albicans SC5314 treated with 2048 mg/l of 
each phytocompound in the same conditions described above but 
monitored by CLSM is shown in Fig. 4. Untreated Candida biofilm 
exhibited high cell viability, while on the treated biofilms, the viability 
decreased significantly, and the amount of dead Candida cells increased. 
CLSM allowed to visualize cell viability of treated and untreated biofilms 
and confirmed the results of metabolic activity assay. 
4. Discussion 
Oral candidiasis is a common superficial infection in immunocom-
promised patients, denture wearers, and in the elderly and new-borns 
[1]. Pseudomembranous candidiasis, erythematous candidiasis, hyper-
plastic candidiasis, denture stomatitis and angular cheilitis are clinical 
manifestations of this Candida infection. Classical treatment of oral 
candidiasis has some important issues mainly related to the develop-
ment of antifungal resistances, the limited availability of antifungal 
agents and their potential toxicity, so new therapeutic alternatives 
should be implemented [15]. Essential oils stand out in the management 
of oral infections because of their antimicrobial activity and have been 
included in oral rinses [6,16]. However, reliable information on their 
potential use in antifungal therapy is scarce. These oils are complex 
mixtures of chemically heterogeneous components obtained from aro-
matic plants that have numerous biological properties including anti-
oxidant, antimicrobial, antitumor and analgesic activities [17–21]. 
While the study of antimicrobial properties of essential oils as a 
Table 2 
Minimum fungicidal concentration (MFC) of carvacrol, cinnamaldehyde and thymol against 35 isolates of Candida.  
Candida species (n)  Carvacrol [2–1024 mg/l] Cinnamaldehyde [2–1024 mg/l] Thymol [2–1024 mg/l] 
C. albicans (10) MFC GM 256 119.4 256 
Mode 256 128 256 
Range MFC 256 64–128 256 
C. glabrata (10) MFC GM 238.9 119.4 238.9 
Mode 256 128 256 
Range MFC 128–512 64–128 128–256 
C. krusei (3) MFC GM 256 64 256 
Mode 256 64 256 
Range MFC 256 64 256 
C. dubliniensis (3) MFC GM 161.3 64 161.3 
Mode 128 64 128 
Range MFC 128–256 64 128–256 
C. parapsilosis (2) MFC GM 256 128 256 
Range MFC 256 128 256 
C. guilliermondii (2) MFC GM 362 64 256 
Range MFC 256–512 64 256 
C. orthopsilosis (2) MFC GM 256 64 256 
Range MFC 256 64 256 
C. tropicalis (2) MFC GM 362 91 256 
Range MFC 256–512 64–128 256 
C. metapsilosis (1) MFC 256 128 256 
Total MFC GM 251.0 99.0 241.2 
Mode 256 128 256 
Range MFC 128–512 64–128 128–256 
GM: geometric mean, MFC: minimum fungicidal concentration. 
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whole has gained considerable interest, comparisons of published results 
is often difficult and has limitations that hinder its clinical application. 
These limitations include the variability among studies due to different 
composition of chemical constituents, the influence of the time of har-
vesting, the part and lot of the plant used or the methodology of 
extraction, and the hypersensitivity reactions associated to their use 
[22]. On the other hand, the study of pure phytochemical compounds 
can present important advantages, as it facilitates the comparison of 
results among research and toxic side effects related to other compo-
nents present in the essential oils are avoided. Moreover, previous 
studies have indicated a significantly superior and sustained inhibitory 
effect of components compared to essential oils [7]. 
Carvacrol and its isomer thymol are monoterpenoid phenols present 
in major proportion in the essential oils extracted from plants of Lam-
iaceae, Verbenaceae, Scrophulariaceae, Ranunculaceae, and Apiaceae 
families [20]. Cinnamaldehyde is a phenylpropanoid present in essential 
oils from several trees from genus Cinnamomum of Lauraceae family 
[21]. In the current study, carvacrol, cinnamaldehyde and thymol 
showed activity against planktonic and sessile Candida cells. In the case 
of planktonic cells, cinnamaldehyde presented the strongest antifungal 
fungicidal activity from low concentrations as reported by Rajput and 
Karuppayil [23], followed by thymol and carvacrol. The latter phyto-
compounds were also very active against all Candida species studied, 
even against isolates with reduced susceptibility or resistance to flu-
conazole, as previously described [24,25]. Although the mode of action 
seems to be directed towards ergosterol synthesis, differences and sim-
ilarities between these phytocompounds could be explained by their 
chemical structure. Carvacrol and thymol both have hydroxyl groups 
and belong to the same chemical class, while cinnamaldehyde would 
exert its greater activity due to its aldehyde group, as hypothesized in a 
study of the inhibitory activity of these compounds via vapor phase 
mediated susceptibility assay [26]. 
Biofilms are communities of adherent sessile cells with different 
properties from those of planktonic cells [27]. Biofilm formation is an 
important virulence factor because the presence of these microbial 
communities is related to increased resistance to antimicrobial agents 
and recalcitrant infections such as denture stomatitis, chronic mucocu-
taneous candidiasis and chronic multifocal candidiasis [1]. In the cur-
rent study, C. albicans was the most biofilm producing species, but also 
C. tropicalis isolates were high biofilm producers. C. tropicalis and 
C. glabrata are frequently co-isolated with C. albicans from patients with 
oral infections or colonization [4,28]. Moreover, co-infection or prior 
infection with C. albicans may facilitate C. glabrata infection [29]. These 
fungal associations could change antifungal susceptibility patterns and 
reduce the effectiveness of conventional treatments for candidiasis [15]. 
In the current study, the three phytochemicals tested and anidulafungin 
have shown anti-Candida biofilm activity, in contrast with the low 
antibiofilm activity of isavuconazole. The last one, a second-generation 
triazole, although active against planktonic fungal cells, was not active 
against Candida biofilms as reported in studies with antifungal agents of 
the same family [30]. Anidulafungin showed activity against almost all 
C. albicans biofilms, although it was not active against C. tropicalis bio-
films, as described in previous reports showing that echinocandins do 
not eradicate or kill C. tropicalis biofilms [31,32]. Comparisons on bio-
film production capacity among different species are subject to a num-
ber of limitations inherent to the methodologies employed due to both 
the methodologies employed and the specific biofilm production pat-
terns of each species. Isolate classification according to biofilm pro-
duction capacity contemplated both metabolic activity and biomass 
results, as recommended by other authors [33]. These procedures are 
broadly used in the literature, despite the lack of standardized meth-
odologies. However, other media did not used in the present work could 
be tested to assess the biofilm production in order to resemble the 
normal conditions in the oral cavity. 
Carvacrol and thymol may be efficient alternatives for eradicating 
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they were more active than cinnamaldehyde in reducing metabolic ac-
tivity and biomass of mature biofilm. Biomass reduction could play a 
crucial role in the management of recalcitrant infections, as biofilms are 
a source for dispersal of cells with advantageous characteristics, such as 
the ability to form new biofilms more efficiently, enhanced adhesion and 
virulence, as reported in mice models of candidiasis [27,34]. Carvacrol 
and thymol reduced at 24 h more than 85% of Candida biofilms meta-
bolic activity of azole-susceptible isolates and until 80% of mature 
biofilms of azole-resistant isolates. These results are supported by the 
CLSM observation of Candida biofilms treated with these phyto-
compounds in which loss of cell viability was evident. Moreover, these 
results are in line with those described by Braga et al. [35], who 
observed a reduction of 45.1% in metabolic activity of C. albicans bio-
film at 6 h of incubation with thymol, 68% inhibition at 12 h and 88.3% 
at 24 h. Similarly, Doke et al. [17] stated that carvacrol eugenol and 
thymol were very effective in reducing >80% of metabolic activity of 
C. albicans biofilm. Dalleau et al. [24] showed that mature biofilms of 
C. albicans, C. glabrata and C. parapsilosis isolates were susceptible to 
carvacrol, geraniol and thymol, even the fluconazole-resistant isolates. 
Carvacrol and thymol are moderately water-soluble and their effec-
tiveness against Candida is associated to cell membrane rupture and 
solubilization, together with ergosterol biosynthesis inhibition [20,36]. 
Cinnamaldehyde, in our study, reduced biofilm metabolic activity 
but its effect on biomass reduction was lower. Moreover, the highest 
Fig. 2. Biofilm growth inhibition of mature biofilms treated with carvacrol, cinnamaldehyde, thymol, anidulafungin and isavuconazole. Metabolic activity (A) and 
biomass (B). Candida albicans: mean of eight isolates including a fluconazole resistant isolate. GC: growth control. * : p < 0.05, * *: p < 0.01 respect to the growth 
control without antifungal agents. 
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activity of this phytocompound was obtained in the early phase, pre-
venting the formation of biofilm. Almeida et al. [16] reported anti--
Candida biofilm activity of cinnamon and its components, among which 
is cinnamaldehyde. The mode of action of cinnamaldehyde against 
biofilm could be related to its capacity to reduce adhesion on biotic and 
abiotic surfaces by downregulating HWP1 gene [18]. This gene is 
involved in hyphal formation on early stages of biofilm development. In 
addition, cinnamaldehyde could cause a loss in cell wall integrity by 
ergosterol depletion [21,23] and an apoptotic effect [18]. 
Oral and denture cleansers that include phytocompounds in their 
formula have been extensively used. However, there are interesting re-
ports that indicate increased C. albicans cell counts from mixed oral 
biofilms exposed to denture cleanser [37]. Therefore, given the impor-
tance of C. albicans in the pathobiology of oral infections such as denture 
stomatitis, dental caries and other biofilm-related clinical presentations 
[38,39], a careful design of the formula of these cleansers should be 
advisable. 
Unlike to the findings of previous studies, our study evaluated bio-
film biomass as an important parameter related to the persistence of the 
biofilm after treatment, and not only with its metabolic activity. Hence, 
the present work provides consistent data on the effect of pure com-
pounds against biofilm formation of different Candida species and 
relevant knowledge about the capacity to remove biomass of mature 
biofilm, thus limiting recurrence. These properties could be promising 
for its application in biomedical fields, such as the design of antifungal 
coatings for biomedical devices from pure phytocompounds avoiding 
the disadvantages of the essential oils described above. 
Nonetheless, limitations of the use of phytocompounds from essen-
tial oils lie in its poor solubility in aqueous solution, volatility and 
instability, and possible hypersensitivity reactions. Furthermore, the 
typical dosage of oral rinses enables only short exposure to phyto-
compounds and may not be suitable to treat active infections. Indeed, 
the clinical applications of pure phytochemical compound may be 
attainable using mainly prolonged release formulations instead of 
cleanser solutions. Nanotechnology can help developing nanoparticles 
with less adverse effects, better bioavailability, less phytocompound 
concentration and site-specific delivery. Cinnamaldehyde could be also 
included in antibiofilm material coatings, while carvacrol and thymol 
can be used to design curative antibiofilm therapy, since carvacrol and 
thymol at concentrations ≤32 mg/l show less cytotoxicity than cinna-
maldehyde in a murine cell line, RAW 264.7 [40]. In addition, likewise it 
has been observed synergistic effect against planktonic cells (Table S2), 
the combination of phytocompounds and antifungal drug in sessile cells 
can improve their antifungal activity. Thus, use of drug combinations, in 
which the phytocompounds would degrade the matrix and other drugs 
exert antifungal actions, could be beneficial to improve the clinical 
response to therapy in candidiasis associated to biofilms, where azoles 
have proven little or no effect [41]. 
5. Conclusion 
The use of phytocompounds from essential oils has potential in the 
improvement of established infections without developing further 
resistance associated to treatment. Carvacrol, cinnamaldehyde and 
Fig. 3. Images of C. albicans SC5314 biofilm by scanning electron microscopic at 500×, 1000× and 5000×. Untreated biofilm (A), biofilm treated with 2048 mg/l of 
carvacrol (B), 2048 mg/l of cinnamaldehyde (C) and 2048 mg/l of thymol (D). 
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thymol are promising alternatives for candidiasis treatment: cinna-
maldehyde by preventing biofilm formation and carvacrol and thymol 
against established biofilms. However, toxicity and viability studies 
must be done in animal models and cellular cultures to establish the 
optimal use of these phytocompounds as antifungal agents in clinical 
assays. 
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